➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for LDE225

Email this page to a colleague

« Back to Dashboard

What is the drug development status for LDE225?

LDE225 is an investigational drug.

There have been 41 clinical trials for LDE225. The most recent clinical trial was a Phase 2 trial.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Basal Cell, and Pancreatic Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

Recent Clinical Trials for LDE225
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI)Phase 1
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsMayo ClinicPhase 1
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell CarcinomaMelanoma Institute AustraliaPhase 2

See all LDE225 clinical trials

Clinical Trial Summary for LDE225

Top disease conditions for LDE225
Top clinical trial sponsors for LDE225

See all LDE225 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.